Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels

被引:17
|
作者
Younossi, Z. M. [1 ,2 ]
Elsheikh, E. [1 ,2 ]
Stepanova, M. [2 ]
Gerber, L. [2 ]
Nader, F. [1 ,2 ]
Stamm, L. M. [3 ]
Brainard, D. M. [3 ]
McHutchinson, J. G. [3 ]
机构
[1] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA
[2] Betty & Guy Beatty Ctr Integrated Res, Inova Hlth Syst, Falls Church, VA 22042 USA
[3] Gilead Sci, Foster City, CA USA
关键词
apoE; apolipoprotein; hepatitis C virus; ledipasvir; ribavirin; sofosbuvir; DENSITY-LIPOPROTEIN RECEPTOR; NEUTRALIZING ANTIBODIES; HUMAN HEPATOCYTES; INFECTION; PARTICLES; HCV; EPIDEMIOLOGY; ENHANCEMENT; SECRETION; BI;
D O I
10.1111/jvh.12448
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The interaction of lipoproteins with hepatitis C virus (HCV) has pathogenic and therapeutic implications. Our aim was to evaluate changes in the apolipoprotein profile of patients with chronic hepatitis C during and after successful cure with ledipasvir and sofosbuvir (LDV/SOF) with and without ribavirin (RBV). One hundred HCV genotype 1 patients who had achieved SVR-12 after treatment with 12 weeks of LDV/SOF +/- RBV were selected from the ION-1 clinical trial. Frozen serum samples from baseline, end of treatment and week 4 of follow-up were used to assay apolipoproteins (apoAI, apoAII, apoB, apoCII, apoCIII, apoE) using the Multiplex platform to assess for changes in the apolipoprotein levels. At the end of treatment compared to baseline, a significant reduction in apoAII levels (-14.97 +/- 63.44 mu g/mL, P = 0.0067) and apoE levels (-4.38 +/- 12.19 mu g/mL, P < 0.001) was noted. These declines from baseline in apoAII (-16.59 +/- 66.15 mu g/mL, P = 0.0075) and apoE (-2.66 +/- 12.64g/mL, P=0.015) persisted at 4 weeks of post-treatment follow-up. In multivariate analysis, treatment with LDV/SOF + RBV was independently associated with reduction in apoE (beta = 5.31 mu g/mL, P = 0.002) (compared to RBV-free LDV/SOF) (P < 0.05). In contrast, apoCII levels overall increased from baseline to end of treatment (+2.74 +/- 11.76 mu g/mL, P = 0.03) and persisted at 4 weeks of follow-up (+4.46 +/- 12.81 mu g/mL from baseline, P = 0.0005). Subgroup analysis revealed an increase in apoCII during treatment only in patients receiving LDV/SOF without RBV (+5.52 +/- 11.92 mu g/mL, P = 0.0007) but not in patients receiving LDV/SOF + RBV (P = 0.638). Treatment with LDV/SOF +/- RBV is associated with a persistent reduction in the apolipoprotein AII and E after achieving cure. These data suggest that treatment with LDV/SOF +/- RBV may be associated with alterations in serum apolipoproteins which could potentially impact viral eradication.
引用
收藏
页码:977 / 982
页数:6
相关论文
共 50 条
  • [1] LEDIPASVIR (LDV)/SOFOSBUVIR (SOF) TREATMENT OF HEPATITIS C VIRUS (HCV) IS ASSOCIATED WITH REDUCTION OF SERUM APOLIPOPROTEIN LEVELS
    Younossi, Z.
    Elsheikh, E.
    Stepanova, M.
    Gerber, L.
    Nader, F.
    Brainard, D.
    McHutchinson, J. G.
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 : S599 - S599
  • [2] Ledipasvir/Sofosbuvir in the Treatment of Hepatitis C Virus Genotype 6
    Nguyen, Andrew A.
    Weisberg, Ilan
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S368 - S368
  • [3] A pharmacokinetic and treatment study of ledipasvir/sofosbuvir in pregnant women with hepatitis C virus
    Chappell, C.
    Kirby, B.
    Scarsi, K.
    Suri, V.
    Gaggar, A.
    Krans, E.
    Macio, I.
    Meyn, L.
    Bogen, D.
    Bunge, K.
    Hillier, S.
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2019, 221 (06) : 666 - 666
  • [4] Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C
    Cuenca-Lopez, Francisca
    Rivero, Antonio
    Rivero-Juarez, Antonio
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (01) : 105 - 112
  • [5] Treatment of Hepatitis C with Sofosbuvir/Ledipasvir in Elderly Veterans
    Blanquicett, C. J.
    Mirk, A.
    Cartwright, E.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 : S100 - S100
  • [6] Is sofosbuvir/ledipasvir safe for the hearts of children with hepatitis C virus?
    Ghobrial, Carolyne
    Sobhy, Rodina
    Mogahed, Engy
    Abdullatif, Hala
    El-Karaksy, Hanaa
    [J]. DIGESTIVE AND LIVER DISEASE, 2019, 51 (02) : 258 - 262
  • [7] Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin
    Globke, Brigitta
    Raschzok, Nathanael
    Teegen, Eva-Maria
    Pratschke, Johann
    Schott, Eckart
    Eurich, Dennis
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2017, 19 (01)
  • [8] Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir
    Jansen, Jeffrey W.
    Powderly, Gillian M.
    Linneman, Travis W.
    [J]. ANNALS OF PHARMACOTHERAPY, 2017, 51 (07) : 543 - 547
  • [10] Generic Ledipasvir-Sofosbuvir Treatment for Adolescents With Chronic Hepatitis C Virus Infection
    Fouad, Hanan M.
    Sabry, Magda A.
    Ahmed, Amal
    Hassany, Mohamed
    Al Soda, Mohamed F.
    Aziz, Hossam Abdel
    [J]. JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2020, 9 (03) : 386 - 389